prices for glp-1 drugs The future of GLP-1s: Cost, access and more trends HR must know GLP-1 use peaks in middle

BPC-157 remains an experimental compound without regulatory approval for human use

Brit J Cancer

Formulation: Multiple-dose sterile solution designed to ensure consistent potency over the usage period

They create repeatable, defensible playbooks Redesign Health and PE-backed operators take something like GLP-1 clinic and turn it into a systematized unit economics

The Regulatory Reality of 2026: What Actually Changed In late 2023, the FDA moved 19 peptides, including BPC-157, to what's known as "Category 2" status under its framework for bulk drug substances used in compounding, identifying them as substances that "may present significant safety risks." The concern, as stated in FDA guidance, centered on the limited large-scale human data and questions about immunogenicity

J Neurochem 1996